Last reviewed · How we verify
NX
Nexium works by reducing the amount of acid produced in the stomach.
Nexium works by reducing the amount of acid produced in the stomach. Used for Erosive esophagitis, Gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome.
At a glance
| Generic name | NX |
|---|---|
| Also known as | Navelbine and Xeloda |
| Sponsor | GBG Forschungs GmbH |
| Drug class | Proton pump inhibitor |
| Target | H+/K+ ATPase |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal |
| Phase | FDA-approved |
Mechanism of action
Nexium, a proton pump inhibitor, blocks the enzyme system in the stomach lining responsible for acid production. This leads to a decrease in gastric acid secretion, which helps to alleviate symptoms of acid reflux and other conditions.
Approved indications
- Erosive esophagitis
- Gastroesophageal reflux disease (GERD)
- Zollinger-Ellison syndrome
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Dizziness
Key clinical trials
- Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial (PHASE4)
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors (PHASE1)
- Non-invasive Monitoring: Impact on Patient Management and Outcomes
- Low-dose Buprenorphine Initiation for Opioid Use Disorder (PHASE4)
- Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma (PHASE2, PHASE3)
- Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease (PHASE2)
- Fetal Haemoglobin and Cerebral and Peripheral Oxygenation.
- Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NX CI brief — competitive landscape report
- NX updates RSS · CI watch RSS
- GBG Forschungs GmbH portfolio CI